September was Blood Cancer Awareness Month. October brings breast and liver cancer to the spotlight. Different organs, different origins, but the same fundamental problem: we still treat cancer as a collection of separate diseases instead of a single engineering challenge with shared constraints. 

Leukemia, breast carcinoma, and hepatocellular carcinoma each have unique microenvironments, immune signatures, and mutational landscapes. However, from an engineering perspective, the systems we use to deliver and validate therapies share far more similarities than differences. Despite that, nearly every therapeutic pipeline still starts from zero. Separate preclinical models, manufacturing runs, and INDs continue to duplicate effort, even when the same delivery scaffold or process could apply across multiple tumor types. The challenge is no longer just scientific; it is also structural, rooted in how we build, validate, and regulate new therapies. 

Building Pathways for Platform Therapeutics 

The FDA approves drugs, not systems. If you change a targeting ligand, a peptide, or a linker, the agency treats it as a new entity with a new IND, new toxicology studies, and a new comparability package. It does not matter that the core delivery scaffold and process controls are identical. That model worked when drugs were small molecules. It falls short when the product is a programmable therapeutic platform. We need a regulatory structure that recognizes validated delivery frameworks in the same way chemistry recognizes reaction templates: once a process has been proven safe and consistent, small, controlled variations do not require rebuilding the entire validation stack. 

The FDA’s Platform Technology Designation for gene therapy signals a step in that direction, and the Regenerative Medicine Advanced Therapy (RMAT) pathway offers another model for accelerating review of biologics addressing serious unmet needs. But oncology still lacks a clear, predictable route. Until such frameworks exist, adaptive platforms will remain constrained by processes designed for single-use drugs. 

Laying the Groundwork for Modular Therapeutics 

Modularity only works when there are reliable, validated components to swap. Tumor-targeting ligands today are still discovered one paper at a time, using different assays, with limited reproducibility. There is no shared repository with standardized data on selectivity, off-target effects, or cross-tissue kinetics. 

To make modularity real, the field needs a deep, validated targeting library. Each ligand should be characterized not only by what it binds but by how specifically it avoids healthy tissue, how stable it remains under formulation stress, and how interchangeable it is across delivery scaffolds. 

Examples from adjacent fields already show the value of modularity. Universal and modular CAR T systems use interchangeable targeting arms to redirect immune cells without rebuilding the entire construct. Nanobody-based conjugates demonstrate that targeting domains can be swapped while the payload and delivery mechanism remain consistent. The challenge now is building the scale and validation depth needed for oncology platforms to consistently function this way. 

Athari BioSciences’ Approach to Programmable Oncology 

At Athari BioSciences, we are designing a cancer-targeting nanoparticle framework intended to deliver therapeutic payloads directly to tumors while minimizing effects on healthy tissue. The goal is to build a modular system where the scaffold remains constant and the targeting module can be adapted for different cancer types. 

Our immediate focus is on establishing the foundations for this platform: 

Developing the design and validation pipeline. We are refining our approach for selecting and characterizing tumor-binding ligands across different cancer models. This early groundwork supports the creation of a scalable and adaptable targeting library. 

Defining standards for interchangeability. We are outlining the experimental and regulatory criteria that will eventually demonstrate when a module can be replaced without repeating foundational safety studies. This framework supports faster adaptation while maintaining rigor. 

Our broader aim is to help define how programmable cancer therapeutics can be developed within existing regulatory structures while maintaining proprietary innovation in the components that make them work. 

From Many Cancers to One System 

Cancer awareness months highlight the diversity of disease, but the next frontier is connecting those efforts into a coherent system. Progress in oncology has produced extraordinary depth within each indication, yet there is little shared infrastructure between them. 

The path forward is not to erase biological differences but to engineer tools that can adapt to them, creating frameworks flexible enough to operate across tumor types without starting from zero each time. 

To move in that direction, the field needs to: 

• Establish regulatory pathways that recognize reusable therapeutic platforms. 

• Develop interoperable component libraries that enable modular design. 

• Define performance standards that measure cross-tumor transferability, not just a single indication of efficacy. 

These represent the foundation of a scalable oncology ecosystem. One cure will never fit all; however, one framework could. Join Athari Bio in advancing the next generation of modular cancer therapeutics. 

A Summer Built Around the Interns 

At Athari BioSciences, Inc. we designed our internship around a simple idea: make the students the center of gravity. This summer we hosted a cohort of nine interns whose experience levels ranged from high school and early academic training to advanced graduate study. Rather than slotting them into preset roles, we selected each intern from a competitive application pool and tailored the program to what they wanted to learn, the skills they wanted to leave with, and the exposure they needed to advance their career goals. That focus shaped every part of the experience. From week one, interns set personal learning objectives, matched with mentors, and built plans that tied daily work to clear outcomes. They did not spend the summer as extra hands on someone else’s project. They led their own. In practice that meant designing studies, defending methods, owning timelines, and being credited as the primary authors and principal drivers of their work. 

The technical bar was high, and the work was real and inspiring. Projects were mapped to Athari Bio’s core mission and had direct paths to impact. Whether in assay development, data analysis, or translational applications, the expectation was that each intern would push beyond demonstration and toward a result that could inform our internal roadmaps or partner-facing deliverables. While our work is specialized, the program was intentionally interdisciplinary. Teams combined biology, engineering, computation, and design thinking to solve problems in more original ways. 

Project Spotlights 

• Microgravity muscle-atrophy gene therapy. Engineered a lentiviral construct to target gene expression in muscle atrophy pathways. The long-term concept explores a biosensor-driven therapeutic and eventual wearable integration amenable for long space flight missions. 

• High-throughput antimicrobial screening with a cell viability assay. Created a fluorescence assay to evaluate gram-negative bacterial growth inhibitors and set the path to OT-2 robot automation.  

• Targeted cancer cell death via HSV1-TK drug system. Engineered lentiviral vectors carrying HSV1-TK variants for targeted cancer death in tumor-targeting nanoparticles. 

• Alphavirus-based pseudovirus assay for rapid antibody neutralization testing. Optimized plasmid production and VLP assembly for a Ha-CoV-2 system, targeting a reduction in readout time from 18 hours to roughly10 minutes using a faster reporter.  

What made the program different was not only what the interns did but how we structured accountability and support. Athari Bio mentors acted as sounding boards and technical advisors while interns maintained ownership. Reviews focused on experimental logic, data quality, and decision-making under real constraints like time, cost, and feasibility. The result was a rare training environment where young, high-achieving people were treated as builders and thinkers who could ship work that matters. This is the internship model we believe the field needs: student-centered, outcomes-driven, technically rigorous, and interdisciplinary by design. It prepares emerging scientists and engineers to lead, not just contribute. It also raises the bar for what a summer at a biotech company can deliver for both the interns and the organization. 

Beyond the bench: professional development that actually moves the needle 

We wanted our interns to leave with more than technical skills. Throughout the summer we ran a focused series of seminars that answered two practical questions: what does a modern lab expect from you on day one? And what does the field expect from you in year five? 

First, CLIA and CAP. We unpacked how accredited clinical labs operate, from quality management systems and documentation discipline to validation vs. verification, control plans, proficiency testing, and inspection readiness. The goal was simple: help students see what “ready for clinical” really means, and how to translate bench experiments into workflows that can withstand regulatory scrutiny. Second, professionalism. We treated communication, transparency, and code of conduct as technical skills. Finally, scientific communication. We covered how to write for impact, design figures that tell a clean story, and present data so decisions are obvious. Students built short talks that moved from hypothesis to result to next step, then field-tested them with live Q&A and peer critique. 

Learning also happened outside the building. Our cohort spent a day at the Howard Hughes Medical Institute’s Janelia Research Campus, meeting scientists, seeing multidisciplinary teams in action, and getting a feel for how complex projects move from concept to tool. The conversations and lab walk-throughs gave students a clear picture of how their skills map to real research environments. 

The program’s approach resonated beyond our walls. Loudoun Now profiled the internship and highlighted the way we put students in the driver’s seat, not on the sidelines. It captured what we hoped people would see in this work at Athari BioSciences: emerging scientists and engineers learning to lead, communicate, and deliver results that matter. 

An Internship Model Where Emerging Scientists Lead 

This internship cohort showed what can happen when you treat emerging scientists and engineers as leaders. They built real tools, generated real data, and practiced the habits that make work reproducible and decision ready. They also learned how to communicate results, operate within quality systems, and navigate professional environments with clarity and confidence. The payoff runs both ways. Our interns left with tangible outputs and a clearer line of sight to their next steps. Athari BioSciences gained new assays, sharper workflows, and a pipeline of leaders who know how to think across disciplines. We will carry these lessons into the next cohort, expanding what worked and raising the bar again. 

If you are a student who wants this level of responsibility, or an educator or partner who wants to collaborate, keep an eye out for our next call for applications. To the mentors, staff, and especially the interns who made this summer exceptional, thank you. You set a new standard for what an internship can be. 

Each World Blood Donor Day, we celebrate how voluntary blood donations give people “a second chance at life” ¹. Donors’ generosity literally saves lives – patients in trauma, surgery, or with chronic diseases often need transfusions of red cells, plasma, and platelets². One unit of donated blood can help up to three patients³ ¹. In 2024, over 118 million units were collected worldwide⁴, yet many countries still face chronic shortages. Increasing voluntary donations is thus a global priority so that all patients can receive safe blood when needed¹ ⁴. 

Beyond treating patients directly, donated blood plays a crucial role in diagnostics. In the lab, each sample is centrifuged into cells and plasma so different tests can be run⁵. The plasma or serum is analyzed chemically – for example, glucose levels for diabetes or liver enzymes for hepatitis – while the cellular fraction is counted and characterized to detect anemia, infection, or malignancy⁵ ⁶. Automated systems routinely perform complete blood counts to flag unusual cell changes⁶. Every donated unit is also screened for infectious diseases like HIV, hepatitis B/C, and syphilis as part of blood bank safety, which additionally provides epidemiological data on disease prevalence. In short, blood from donors fuels diagnostics. It not only supports patient care but also fuels research: many blood services now ask donors to contribute extra samples to biobanks. These longitudinal samples allow researchers to study genetics, disease susceptibility, and biomarker evolution over time⁷. 

Evolution of Blood Testing and Diagnostic Technologies 

Laboratory diagnostics have come a long way. Early tests like the Gram stain (1882) distinguished bacterial species by their cell walls, while microscopes and manual counts gave crude clues about disease⁶. The Coulter counter (1940s) helped in automation for blood-cell counts⁶. A true revolution came with the development of polymerase chain reaction (PCR) in 1986, which allows for detection of minuscule amounts of pathogen DNA or genetic mutations with high sensitivity⁸. 

Today’s labs deploy a range of tools. Mass spectrometry can identify pathogens by their protein fingerprints⁸. CRISPR-based diagnostics are emerging to detect specific DNA sequences for viruses or genetic diseases⁹. Next-generation sequencing (NGS) offers real-time pathogen surveillance and precision diagnostics⁹. Microfluidic devices, wearable biosensors, and point-of-care platforms are bringing high-complexity diagnostics into primary care and home settings¹⁰. AI now supports pattern recognition in vast diagnostic data sets¹⁰. 

Together, these innovations mark a shift toward rapid, multiplexed, and highly sensitive testing platforms that enhance both personal care and public health response. 

Linking Diagnostics to Global Health Goals 

Access to diagnostics is now recognized as essential to achieving universal health coverage. In 2018, the World Health Organization (WHO) released its first Essential Diagnostics List, outlining over 100 in vitro tests needed for key diseases and health system functions¹¹. WHO emphasized that “an accurate diagnosis is the first step to getting effective treatment”¹¹. No one should suffer or die due to the lack of diagnostic services. 

This principle aligns with the mission of World Blood Donor Day. WHO urges governments to invest not just in blood supply but also in lab systems that ensure transfusions are safe and that diagnostic capabilities are universally available¹. From maternal care to epidemic preparedness, diagnostics and blood systems are interlinked pillars of resilient health care⁴. 

Athari Bio’s Dual-Reporter Assay Platform: A Next-Generation Diagnostic Tool 

Athari BioSciences is simplifying and accelerating diagnostic testing through our dual-reporter neutralization assay platform. This next-gen platform simultaneously measures viral infectivity and host cell viability using engineered pseudotyped reporter viruses¹². 

Key advantages include: 

• Parallel readouts: The assay combines a luminescent signal to track infection with a fluorescent signal to assess cell health. This enables differentiation between antiviral action and general cytotoxicity¹². 

• Minimal input and fast turnaround: Only 80 microliters of blood is required, and results are available in about six hours. This is a major time savings over traditional plaque reduction tests¹². 

• High correlation to gold-standard PRNT: In benchmarking studies, the assay achieved a correlation of R² ≈ 0.98 with plaque reduction neutralization tests (PRNT), the current gold standard¹². 

• Improved specificity: The dual readout avoids false positives from toxic compounds, distinguishing antiviral activity from cell death¹². 

• Flexible design: The platform is built on virus-like particles that can be adapted to new viral strains or entirely different pathogens¹². 

Already CLIA-validated, the platform holds promise for decentralized immune monitoring and rapid surveillance of emerging variants. It also opens new doors in complex inflammatory conditions, where precise discrimination between immune responses and off-target effects is needed¹². 

Conclusion 

On World Blood Donor Day, we recognize that blood donation saves lives in more ways than one. Beyond transfusion, it empowers diagnostics, fuels research, and enables innovation. As technology advances, the value of each drop of donated blood multiplies. Tools like Athari Bio’s dual-reporter assay illustrate how new platforms can maximize insight from minimal samples, reinforcing the global importance of safe blood systems and cutting-edge diagnostics. 

Every drop of donated blood carries potential far beyond the transfusion bag. By investing in next-generation diagnostics, we can unlock that potential by making testing faster, smarter, and more accessible. At Athari BioSciences, we’re building the tools to make it happen. Join us in pushing the boundaries of what blood can tell us. 

References 

1. https://www.who.int/campaigns/world-blood-donor-day/2024 

2. https://www.cdc.gov/blood-safety/hcp/diagnosis-testing/?CDC_AAref_Val=https://www.cdc.gov/bloodsafety/basics.html 

3. https://www.nhlbi.nih.gov/education/blood/donation 

4. https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability 

5. https://pubmed.ncbi.nlm.nih.gov/11933579/ 

6. https://www.ncbi.nlm.nih.gov/books/NBK593683/ 

7. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001779 

8. https://www.sciencedirect.com/science/article/abs/pii/S0009898116302832?via%3Dihub 

9. https://www.science.org/doi/10.1126/science.aam9321 

10. https://www.nature.com/articles/nature05064 

11. https://www.who.int/news/item/19-10-2023-who-releases-new-list-of-essential-diagnostics–new-recommendations-for-hepatitis-e-virus-tests–personal-use-glucose-meters 

12. https://www.athari.bio/athari-biosciences-at-wvc-2025-engineering-precision-platforms-for-a-new-era-of-vaccine-development/ 

Each May, a sea of gray ribbons serves as a powerful reminder of the fight against brain tumors. Brain Tumor Awareness Month, often called “Gray May” for the color of its awareness ribbon, is a time when communities around the world unite to honor those affected, educate the public, and rally support for urgently needed research. For a disease that is too often overlooked, this dedicated month highlights the urgent challenges faced by brain tumor patients and the resilience of a community determined to overcome them.

Unlike some cancers that have seen dramatic improvements in outcomes over the years, progress against malignant brain tumors has been limited.¹ Brain tumors, whether malignant or benign, can have devastating effects on patients’ lives, causing lasting physical, cognitive, and emotional challenges.² Malignant brain cancers in particular often do not respond well to standard therapies, and new effective treatments have been disappointingly scarce in recent decades ¹. Brain Tumor Awareness Month shines a light on these realities. It pushes researchers, clinicians, and the public to recognize that more must be done: more research funding, more clinical trials, and more support for those facing the disease.

By the Numbers: The Urgent Case for Brain Tumor Advocacy and Funding

Brain tumors (which include both malignant brain cancers and benign tumors of the brain and central nervous system) are comparatively rare but have a disproportionate impact. Over 1 million Americans are currently living with a primary brain tumor, and an estimated 93,000 or more will be diagnosed in the United States in 2025 alone. ^2,3 About 72% of brain tumors are non-malignant (benign) and 28% are malignant cancers. ² Benign tumors can often be treated successfully, but they may still cause serious neurological problems due to their location. Malignant brain tumors, on the other hand, are among the deadliest of all cancers. Yet, despite the daunting numbers, there is reason for hope. The brain tumor community of patients, caregivers, doctors, scientists, and advocates are rallying like never before to change the narrative. Fundraising events such as the annual “Race for Hope” in Washington, DC and advocacy campaigns such as NBTS’s “Head to the Hill,” where survivors and loved-ones lobby Congress for research funding are making an impact.³

Precision Medicine in Brain Tumor Research

For decades, treating malignant brain tumors, especially aggressive types like glioblastoma, has been an uphill battle. The standard regimen for glioblastoma (surgery followed by radiation and chemotherapy) only extends life modestly, and no significantly life-prolonging new drug had emerged in over 20 years. The drug vorasidenib was approved by the FDA in 2024 for treating low-grade gliomas with IDH1 or IDH2 genetic mutations. Patients taking vorasidenib had a median of 27.7 months without tumor growth, versus 11.1 months in the placebo group.⁴ This is a strong example of how understanding a tumor’s genetics can lead to tailored treatments that dramatically improve outcomes. At Athari BioSciences, we believe this is exactly where the future of brain tumor care is headed. Our work in genomic profiling and diagnostics supports the shift toward precision medicine — enabling more accurate identification of tumor subtypes and genetic mutations. This is especially critical in neuro-oncology, where insights like detecting IDH mutations can guide the use of targeted therapies.

One Story Among Thousands: Megan and the Reality of Brain Tumors

Behind every statistic and scientific paper are real people. Patients bravely fighting, families caring for loved ones, and survivors who become advocates that inspire us to keep pushing for change and remind us of what’s at stake. Among them: Megan, age 15, from Texas.

In late 2024, Megan began suffering from relentless headaches and vision problems. The diagnosis was every parent’s nightmare: a brain tumor pressing on her optic nerves and causing her to lose vision. Yet thanks to the expertise at a pediatric hospital and a complex surgery, Megan’s story became one of hope. In May 2025, it was reported that she is now cancer-free after a successful treatment that not only removed the tumor but also restored her vision. Her mother describes the journey, from fear and uncertainty to relief and gratitude, and now their family is using her story to spread awareness about the importance of early detection and expert care.⁵ Megan’s experience is just one example among many. There are survivors who have beaten incredible odds, and others who, even in the face of terminal diagnoses, choose to spend their time raising awareness so that future patients might have it better.

As Brain Tumor Awareness Month comes to a close, the work continues.
The urgency doesn’t fade on May 31st, and neither should our commitment. Progress depends on staying informed, supporting organizations and innovators driving research forward, and keeping patients and families at the center of everything we do.

At Athari BioSciences, we are advancing precision diagnostics and genomic tools to help make brain tumors more predictable and more treatable. We’re proud to stand alongside those working toward a future where a diagnosis no longer brings fear, but real options. Gray may be the color of brain tumor awareness, but it stands for a silver lining of hope and the promise that through science and solidarity, we will conquer this challenge.

If you’re interested in partnering, learning more, or exploring our technology, reach out. We are always open to collaboration.

References

1. https://www.ivybraintumorcenter.org/blog/brain-tumor-awareness-month/
2. https://braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/
3. https://braintumor.org/events/brain-tumor-awareness-month/
4. https://neurosurgery.duke.edu/news/new-therapy-glioma-receives-fda-approval
5. https://www.texaschildrens.org/content/patient-stories/may-brain-tumor-awareness-month-life-changing-treatment-texas-childrens

At the World Vaccine Congress 2025, held at the Walter E. Washington Convention Center in Washington, D.C., global leaders in immunology, vaccine science, and biosecurity convened to shape the future of pandemic preparedness and immunotechnology. Athari BioSciences was honored to join this event, showcasing our next-generation neutralizing antibody assay—a dual-reporter platform engineered for speed, clarity, and flexibility in immune surveillance  and therapeutic assessment.

Inside the Platform: Dual-Reporter Assay for Neutralization and Cytotoxicity

We are focused on addressing one of the most pressing needs in infectious disease research: improving how viral immunity and treatment responses are measured. Our goal is to develop tools that function across the full spectrum of use—from laboratory research to clinical settings to field deployment.

The core innovation we brought to the World Vaccine Congress is our dual-reporter neutralizing antibody assay, which simultaneously measures viral infectivity and cell viability in one streamlined, high-throughput test. Developed in collaboration with Virongy BioSciences and leveraging hybrid alpha-pseudovirus technology, the assay overcomes critical limitations of conventional methods:

• Is safely performed in a BSL-2 lab, avoiding the higher safety requirements and cost burdens of BSL-3 containment.
• Measures infection and cytotoxicity in parallel using dual luminescent and fluorescent signals, enabling distinction between viral entry and cell death in a single readout.
• Delivers results within six hours, a significant improvement over the multi-day timeline of the Plaque Reduction Neutralization Test (PRNT), the current gold standard for assessing neutralizing antibodies. This enables faster decision-making in early-phase therapeutic and vaccine development.

The platform both quantifies viral entry and independently measures  cytotoxicity, allowing researchers to confidently distinguish true antiviral effects from false positives due to compound toxicity—a limitation that often compromises traditional single-reporter assays. Requiring only 80 µl of blood, it is well-suited for at-home collection, fingerstick sampling, and decentralized deployment. In benchmarking studies, the assay demonstrated strong correlation with the gold-standard Plaque Reduction Neutralization Test (PRNT), achieving R² values of 0.98 for sensitivity and 0.92 for specificity. These results position the platform as a robust candidate for immunobridging to infer effectiveness of a new drug or vaccine candidate in clinical trials.

Platform Engineering: Modular Design for Rapid Adaptation

The foundation of this assay is a hybrid virus-like particle (VLP) system, initially developed for any variant of SARS-CoV-2. It combines a rapidly expressing alphavirus reporter genome with structural viral proteins, including spike (S), membrane (M), nucleocapsid (N), and envelope (E), creating a non-replicating pseudovirus that closely mimics native viral architecture, which can be safely tested in a BSL-2 laboratory. Unlike spike-only lentiviral systems, our expanded structural protein -VLP design enhances antibody recognition, more accurately reflecting real-world immune interactions. The modular design ensures rapid adaptation to virtually any virus with a known envelope sequence, including Influenza A/B, RSV, Nipah, Lassa, and emerging viral threats.

Why Dual-Reporter Technology Is Essential

Emerging viral threats consistently outpace conventional assay frameworks, as seen with rapidly evolving SARS-CoV-2 variants and other zoonotic threats. Traditional neutralization methods have become too slow, fragmented, and dependent on restrictive containment environments to meet contemporary demands. Our dual-reporter assay addresses these critical issues by enabling real-time cross-validation between infection and toxicity, accelerating candidate triage, and preventing false positives caused by toxic compounds mistakenly flagged as antiviral.

A practical demonstration of this advantage came from our evaluation of inhibitors against H5N1 influenza. In side-by-side testing, the assay clearly differentiated the antiviral activity of Tamiflu from the cytotoxic effects of Puromycin. A single-reporter system might have misclassified Puromycin as an effective inhibitor due to signal loss from cell death. Traditionally, identifying cytotoxicity would require a separate assay, doubling the workload to confirm what our platform reveals in a single readout.

Expanding Applications: From Bench to Clinical and Public Health

Initially designed for viral neutralization testing, our assay has rapidly evolved into a multifunctional platform applicable across research, diagnostics, and public health surveillance.

• In research, it allows deep exploration into immune correlates of protection, efficacy of new drug and vaccine candidates, and viral pathogenesis.
• Clinically, the assay is a a CLIA-validated  Laboratory Developed Test (LDT), with potential for future clinical diagnostic applications.
• In public health, it offers a rapidly deployable, scalable surveillance solution for ongoing monitoring of current viral pathogens and outbreak management of emerging viral threats.

Additionally, the platform may have predictive biomarker potential for conditions like Long COVID. Because the assay precisely distinguishes functional neutralization from persistent inflammatory responses, it could help clinicians and researchers correlate specific immune profiles with lingering symptoms. This insight represents a significant step toward more personalized therapeutic interventions and diagnostic precision for complex post-infectious syndromes.

Looking Ahead: Precision as Global Health Infrastructure

The discussions at WVC 2025 reaffirmed an essential principle: scientific precision must transition from concept to operational standard. Athari BioSciences is actively contributing to this transition, developing tools that transform complex biological information into fast, actionable insights suitable for field deployment, clinical precision, and rapid pandemic response. Our goal extends beyond adapting to the current landscape; we aim to define the future of global health infrastructure through innovation that anticipates rather than reacts.

We invite collaborators, investors, and public health leaders to join us in this critical effort to reshape how the world responds to viral threats. The future of immunosurveillance and rapid assessment of new drug and vaccine candidates isn’t a distant vision. At Athari BioSciences, we’re building it now—through platforms designed for precision, speed, and global deployment.

Every four minutes, someone is diagnosed with colorectal cancer, and every 9 minutes, someone dies from it.¹ Yet despite how common it is, it remains one of the least talked about, and most preventable, cancers today. 

This year, we honor the resilience and advocacy of Bryce Ramsey, a nurse, survivor, and the reigning Mrs. Mississippi Plus America, who is turning her personal battle into a powerful platform to save lives. 

The Silent Shift: CRC is Hitting Younger Adults 

Colorectal cancer (CRC) was once thought to be an “older adult’s disease.” However, according to Dr. Shyam Thakkar, a professor of gastroenterology at West Virginia University, colorectal cancer is the second leading cause of cancer-related deaths in the U.S., with around 50,000 lives lost each year. While rates in older adults are declining, he notes a troubling rise in cases among adults under 50, thus prompting a shift in screening guidelines and a renewed urgency in prevention.² 

Bryce’s Story: Listening to Her Body, Defying the Odds 

At just 33 years old, Bryce noticed blood in her stool. Like many, she first chalked it up to hemorrhoids, which a common issue for nurses who are on their feet all day, and for women post-pregnancy. But as a trained nurse, Bryce knew that blood in the stool can also be a red flag for something far more serious. 

Her doctor listened. And that colonoscopy? It saved her life. Bryce was diagnosed with stage III colon cancer, an advanced stage that many don’t survive. She immediately began treatment: surgery followed by chemotherapy. Doctors warned her that the chemo could affect her fertility. But Bryce is a believer, and God had other plans. Just three months after completing treatment, Bryce found out she was pregnant. Today, she’s the proud mother of a healthy, thriving four-year-old: her “miracle baby.” 

A Crown with Purpose 

Now nearly five years in remission, Bryce has transformed survivorship into leadership. As Mrs. Mississippi Plus America, she’s using her crown to fight for prevention, education, and early detection. Her mission is especially urgent for communities like her own in Mississippi, where access to care, stigma, and misinformation still create deadly delays. 

Screening Saves Lives 

Here’s the truth: colorectal cancer often grows silently. By the time symptoms show up (like blood in stool, unexplained weight loss, or persistent fatigue), the disease may already be advanced. That’s why screening is essential. 

There are several screening options: 

• Colonoscopy: Considered the gold standard. It allows doctors to remove polyps before they turn into cancer. 

• FIT (Fecal Immunochemical Test): A non-invasive stool test done at home. 

• Stool DNA tests (e.g., Cologuard): Another at-home option that looks for altered DNA and blood in your stool. 

Not all tests are the same, but something is always better than nothing. This March, make the call. Ask your doctor about your risk. Share this blog with a loved one. And if you’re 45 or older, schedule your screening. It’s not just your health, it’s your life. And it’s worth protecting. 

Conquering Cancer with Science: Athari BioSciences 

At Athari BioSciences, we are pioneering a precision-targeted approach to treating aggressive cancers like colorectal cancer. Our platform uses engineered nanoparticles to deliver gene-modulating therapies and chemotherapeutic payloads directly into tumor cells, targeting cancer at the molecular level while minimizing harm to healthy tissue. Our goal is twofold: to improve survival rates and to enhance quality of life for patients, particularly in communities that face disproportionate cancer burdens. By investing in next-generation cancer therapeutics, we hope to not only improve outcomes for patients diagnosed with CRC, but also change the standard of care.  

Special thanks to the Colorectal Cancer Alliance for sharing Bryce Ramsey’s powerful survivor story. As a national nonprofit dedicated to ending colon and rectal cancers, the Alliance plays a key role in raising awareness, supporting patients, and advancing prevention efforts. For more patient stories and resources, visit colorectalcancer.org. 

References: 

1. Benson AB 3rd. Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm. 2007;13(6 Suppl C):S5-S18. doi:10.18553/jmcp.2007.13.s6-c.5 

2. Biese A. Raising Awareness for Colorectal Cancer, On the Rise in Younger Adults. Curetoday. Published March 25, 2025. Accessed March 25, 2025. https://www.curetoday.com/view/raising-awareness-for-colorectal-cancer-on-the-rise-in-younger-adults 

Athari BioSciences stands at the intersection of biotechnology and innovation, driven by a team of forward-thinking researchers and problem-solvers dedicated to pushing the boundaries of science and technology. But what is the essence of working at Athari Bio? To uncover this, insights were gathered from three of our exceptional Associate Research Scientists Mahaniya, Gideon, and Sanskruthi, who shared their experiences, perspectives, and the qualities that make Athari Bio a truly distinctive environment for growth and innovation. 

A Pathway into Biotech: Internships that Open Doors 

For many young professionals, stepping into the life sciences industry can be daunting due to the highly specialized knowledge required, the fast-paced evolution of technology, and the competitive nature of securing meaningful research opportunities. Athari Bio actively cultivates opportunities for emerging talent, providing a space where young professionals can gain hands-on experience and grow within the field. Mahaniya first learned about the company while applying for internships in college. “I ended up getting the internship and interned from June – August 2023. Hands down one of my favorite summers ever!” she shares. 

For Gideon, his journey to Athari Bio was shaped by his passion for research and technology. With a degree in Biology and a minor in Chemistry from VCU, he had already gained extensive experience in cancer research, molecular biology, and cell culture. However, his growing interest in coding and computational applications led him to biotechnology. “My combined background in medicine, research, technology, and biotechnology ultimately led me to Athari Biosciences, where I saw an opportunity to apply my skills in a cutting-edge research environment.” 

Sanskruthi, who completed her bachelor’s in biology and a master’s in molecular biology from George Mason University, was drawn to Athari Bio for its impact-driven research. “It’s often people ask me what I’m racing to finish, but I don’t see why I should take my time when I know exactly what I want to do—which is to make a significant influence on today and the future’s public health issues. And what better way to collaborate and work with a team like Athari’s who are already making a huge impact with their work?” 

The Dynamic Nature of Work at Athari Bio 

One of the most exciting aspects of working at Athari Bio is that no two days are the same. The company fosters a multidisciplinary approach where employees can engage in both scientific research and business development. 

For Mahaniya, her day-to-day work involves proposal planning, data analysis, and lab procedure optimization. With her bioinformatics background, she also works with specialized software to tackle complex problems. “Athari Bio has given me a perfect way to venture into the world of biotechnology as a very recent college graduate! I am able to get accustomed to both the lab work and the business development aspects of the company.” 

Gideon, on the other hand, plays a critical role in lab operations. His responsibilities include inventory management, lab maintenance, and overseeing quality control in research processes. “I am responsible for supply chain documentation, meticulously recording each sample’s size, volume, lot number, catalog number, and more to ensure proper organization and traceability within the lab.” Beyond logistics, he also works on cell culture maintenance, cell-based assays, and molecular biology techniques, ensuring high experimental accuracy. 

For Sanskruthi, her daily routine revolves around designing and optimizing experiments. “Thinking about experiments, running experiments, optimizing experiments, analyzing experiments, and repeating that entire process perpetually. With little in-between snack times, of course.” Her structured and methodical approach plays a crucial role in advancing Athari’s research initiatives. 

A Culture of Mentorship and Growth 

What sets Athari Bio apart is its commitment to continuous learning and professional development. Mahaniya, Gideon, and Sanskruthi emphasized how the company fosters a collaborative environment where mentorship plays a key role in career advancement. 

“Athari Bio ensures that employees have the tools they need to develop their skills and advance in their careers. The emphasis on growth, mentorship, and collaboration makes it an inspiring place to work,” says Gideon. 

Additionally, Athari Bio fosters a culture of adaptability and collaboration, ensuring that employees have the resources and support they need to thrive in both their personal and professional journeys. “Everyone at Athari Bio is down-to-earth, approachable, and genuinely invested in helping each other succeed, which creates a strong sense of teamwork and support,” Gideon shares. 

Bridging Science, Technology, and Innovation 

Both Mahaniya and Gideon highlight how their work at Athari Bio allows them to bridge multiple disciplines. Whether it’s using bioinformatics for data analysis, maintaining laboratory efficiency, or integrating computational techniques into research, these Associate Research Scientists at Athari Bio are constantly engaged in cutting-edge scientific exploration. For Sanskruthi, one of the most exciting aspects is drug discovery. “We go from screening or testing hundreds of drugs and don’t even realize one of the drugs may be the solution to a significant health challenge” The potential to contribute to groundbreaking solutions keeps her motivated, and the integration of experimental and computational approaches makes this work even more impactful. 

As a launchpad for scientists, innovators, and problem-solvers, Athari Bio’s culture and values focus on curiosity, collaboration, and continuous learning. Our employees aren’t just part of a company; they’re part of a mission. The mission to make an impact, just as the name Athari means. 

Our name Athari embodies our purpose: to make a meaningful impact on the world through groundbreaking biological solutions. Come join the impact movement by learning more about open positions and opportunities to partner with us. 

At Athari BioSciences, the Swahili word for impact drives a relentless commitment to advancing global health through groundbreaking discoveries. Founded to forge connections between cutting-edge research and accessible healthcare, Athari BioSciences operates at the vital intersection of technology, diagnostics, and public health. This pioneering small business transforms the healthcare landscape by empowering communities, developing life-saving solutions, and inspiring the next generation of STEMM leaders.

Four visionary leaders kindle Athari’s progress, each bringing distinctive expertise and passion to the company’s mission. From redefining cancer therapeutics to revolutionizing immunosurveillance and vaccine delivery, Susan Mitchell, Dr. Tammey Naab, Dr. Tshaka Cunningham, and Jeannett Jackman unite as a dynamic team that sparks ingenuity and systematic efficiency. Together, they breathe life into Athari Bio’s mission of transforming lives through science, mentorship, and trailblazing advancements.

Why Athari Bio? A Shared Commitment to Impact

For Susan Mitchell, founding Athari BioSciences represents the culmination of a journey shaped by faith, ingenuity, and purpose. Reflecting on her mission, she says, “I have to do this work because my mentees, colleagues, and community are relying on me.” Her vision for Athari Bio emerged from her determination to strengthen STEMM training and advance translational research and technology transfer across sectors. She notes, “There are a lot of organizations providing young people with experiences that usually take up a day, but nobody is willing to address the root challenge – over 2.5 million unfilled biomedical jobs that threaten our nation’s health security and scientific workforce.” Athari Bio serves as the catalyst for STEMM workforce development, streamlined execution, and cross-sector collaboration. Through strategic partnerships between academia, industry, government, and American citizens, she forges pathways that accelerate scientific discoveries from laboratory to market, ensuring breakthroughs benefit those who need them most.

Dr. Tammey Naab sees Athari as an opportunity to merge her extensive clinical expertise with her commitment to pioneering research. Drawn to the company’s culture and thought leadership, she says, “Susan’s dynamism, her government connections, and Tshaka’s genius make this a very interesting intellectual endeavor for me.” Athari Bio empowers Dr. Naab to develop advanced clinical trials and transformative diagnostic solutions, enhancing precision in medical research.

For Dr. Tshaka Cunningham, Athari Bio’s mission to advance scientific excellence resonates deeply. He envisions the company as a catalyst for transformation: “What inspires me most is how we embody our name through action – creating jobs locally, training tomorrow’s scientists, and developing technologies that improve human health globally.” This vision aligns perfectly with his lifelong passion for biomedical research and revolutionizing healthcare delivery.

Jeannett Jackman discovers in Athari the perfect fusion of her expertise in government contracting and breakthrough biotechnology solutions. Describing her role, she says, “What makes my role particularly interesting is how it connects scientific advancement with business success. At Athari Bio, I get to help build something meaningful.” Athari empowers her to apply her skills to a mission-driven organization that champions systematic efficiency and real-world impact.

The projects led by the Athari BioSciences team showcase their collective expertise in creating solutions that matter. From cancer therapeutics to oral vaccines and genomic education, each initiative demonstrates their commitment to advancement. Dr. Tshaka Cunningham, who leads the development of “Cancer Targeting Nanoparticles,” shares, “The potential impact of the work we’re doing here… the net result is saving lives. It is an incredibly noble cause.” Dr. Tammey Naab’s contributions to the oral vaccine platform stem from her meticulous attention to safety and efficacy, as she explains, “Any time you develop a product for humans, you must be totally transparent with results and constantly refine it for the best possible outcome.” As COO, Jeannett Jackman brings these projects to life by creating operational structures that support growth, noting, “I ensure our operational excellence matches our scientific ambition.” Together, the team’s unique skills and unwavering enthusiasm propel Athari Bio’s mission to deliver transformative healthcare solutions.

Excellence powers every aspect of Athari BioSciences, a value that CEO Susan Mitchell places at the core of the company’s mission. “The value that resonates the most is excellence because when you put excellence on all these activities, all goals are met,” Susan shares. Her leadership ensures that every project reflects this principle, from pioneering infectious disease countermeasures to launching initiatives like the Genomic Education Mentors & Scientists (GEMS) program. She finds deep motivation in the impact Athari Bio creates for STEMM mentees, colleagues, and community, adding, “When I get discouraged, I look at the young people in our ecosySTEMM… they’re watching and waiting for me to show them a way.” Under her guidance, merit serves as a catalyst that drives the company’s inventive spirit and transformational achievements.

The Road Ahead: Where Science Meets Purpose

The future of Athari BioSciences shines as bright as the team that is driving it forward. With groundbreaking research milestones on the horizon, the company stands ready to spark rapid growth and global impact. Dr. Tshaka Cunningham envisions a future where Athari Bio’s technologies reach commercialization, saying, “I am excited to see the company meet its product development goals and move forward with some of the exciting research. Once we hit those milestones, I see us growing at a rapid pace.” For Dr. Tammey Naab, the focus remains on refining processes and delivering excellence: “The finish line is completing validation, so it is easy enough to do in a clinical lab, high-throughput, and without adverse effects.” Together, the team charts Athari’s course toward a reimagined healthcare landscape.

2024 marked a transformative year for Athari Biosciences that solidified our position at the intersection of healthcare innovation and social impact. As we reflect on our milestones and growth, one thing remains constant: our unwavering belief in forging a new path towards more equitable, effective, and accessible healthcare solutions. Our CLIA-certified BSL2 diagnostic, research, and training laboratory in Sterling, VA continues to serve as a hub of innovation, where our team of scientists and experts collaborates to develop next-generation therapeutics, vaccines, and diagnostics. We’re not just a biotech company; we’re a community partner committed to improving health outcomes for all, advancing scientific knowledge, and cultivating a more skilled workforce in the life sciences. Our three interconnected lines of business—federal contracting, STEMM workforce development, and a fully operational CLIA, BSL2 lab—constitute a robust pipeline encompassing product commercialization, population health strategies, and clinical services.   

Transforming Cancer Therapeutics

Central to our mission is developing next-generation cancer therapeutics that address urgent and unmet medical needs, particularly in historically underserved communities. Athari Bio’s chief technical officer and nationally-renowned molecular biologist, Dr. Tshaka Cunningham, is pioneering “Cancer SMART PARTICLES”— a proprietary targeted molecular therapeutic that selectively target biomarkers commonly found in breast cancer cells. Our approach leverages nanoparticle engineering to deliver anti-cancer genes and chemotherapeutic payloads directly into tumor cells, sparing healthy tissue and thereby minimizing adverse effects. Our goal is to improve survival rates and quality of life, particularly for individuals who often face disproportionate cancer burdens.  

Reimagining Immunization with an Oral Vaccine Platform

Another critical initiative we’re undertaking is the development of an innovative oral vaccine development platform. With this platform, we’re reimagining vaccine delivery, stability, and accessibility. Our proprietary nanoparticle-based formulation is designed to survive stomach acid conditions, deliver immunogens to the small intestine, and promote both mucosal and systemic immune responses. Our oral vaccines have the potential to dramatically simplify distribution, bypass the need for cold chains, and strengthen the global fight against infectious diseases by rapidly protecting populations during outbreaks. 

Neutralizing Antibody Platforms for Rapid and High-Throughput Immune Assessment

Beyond preventing disease, Athari BioSciences focuses on strengthening our response capabilities through advanced viral immunosurveillance and neutralizing antibody platforms. Our research leverages nonreplicating hybrid alphavirus-SARS-CoV-2 to rapidly quantify neutralizing antibodies against evolving viral variants. This enables high-throughput screening and immunological insights, guiding public health agencies, pharmaceutical developers, and research institutions in their fight against emerging pathogens. Ultimately, our platform bridges critical knowledge gaps, accelerating the evaluation of vaccine efficacy for proactive global health preparedness. 

Empowering the Next Generation through Workforce Training

At the heart of Athari BioSciences’ vision is the unwavering commitment to fostering an  accessible and dynamic life sciences workforce. Through the “Future STEMM Leaders” program, we accelerate the careers of STEMM students and emerging professionals entering the life sciences industry, allowing them to gain meaningful employment, and drive impactful health innovations. Our students receive hands-on training in our CLIA lab, working on impactful research and acquiring capabilities that are highly desirable to future employers. Our partner employers benefit from access to a highly skilled, distinctive talent pool, while learners find fulfilling career pathways that ultimately contribute to better population health outcomes.  

Complementing this initiative, we’re thrilled to announce the launch of Genomic Education Mentors & Scientists (GEMS), a nonprofit organization dedicated to advancing genomic science through education, mentorship, and research. GEMS is transforming the future of healthcare by building the next generation of genomics leaders. Through intensive mentorship and hands-on training, GEMS empowers promising students to become pioneering scientists capable of addressing humanity’s greatest health challenges. From tackling devastating diseases to enhancing biosecurity measures, GEMS ensures that genomic advances benefit all communities equitably. This effort aligns with Athari BioSciences’ broader mission of bridging healthcare disparities and fostering innovation. 

By weaving together pioneering research platforms, targeted therapeutics, innovative vaccine technologies, and dynamic educational programs like Future STEMM Leaders and GEMS, Athari BioSciences exemplifies a holistic approach to health innovation—one that propels science forward, lifts communities, and paves the way for a more resilient global healthcare ecosystem. 

November marks Alzheimer’s Awareness Month, a time to bring attention to a disease that affects millions and ripples through families, communities, and the healthcare system. Alzheimer’s disease is a complex condition that strips away memories, independence, and often, the sense of self. At Athari BioSciences, we are committed to exploring innovative solutions to the challenges of Alzheimer’s through the lens of genomics, while also amplifying the human stories behind the science. 

To deepen our understanding, we spoke with Vania, a nurse manager who works closely with Alzheimer’s patients, and Michelle, a granddaughter who has been at the heart of her family’s caregiving journey. Their insights offer a vivid picture of the emotional, physical, and societal impact of this disease, as well as the resilience it demands from everyone involved. 

Understanding Alzheimer’s 

Alzheimer’s is more than just forgetfulness—it’s a neurodegenerative disease that progressively damages the brain, leading to cognitive decline, memory loss, and ultimately, an inability to perform basic bodily functions. It’s a terminal condition, and its impact is profound not only for the individuals diagnosed but also for their families and caregivers. As Vania explained, “Alzheimer’s is one of the dementias that is ultimately terminal. So, the challenge is to keep the quality and richness of life for as long as possible while addressing their health and engagement.” This delicate balance of preserving quality of life while navigating the inevitability of decline defines much of the caregiving experience. For families like Michelle’s, it’s a journey filled with tough decisions, sacrifices, and moments of bittersweet joy. 

The Challenges of Caregiving 

For Michelle, caring for her grandmother meant stepping into a role she never anticipated. The transition wasn’t easy, particularly when it came to honoring her grandmother’s wishes while prioritizing her safety. “She always told us, ‘If you want to kill me, put me in a nursing home.’ So doing this was really hard. But we knew we had to, for her own good.” Michelle and her family delayed the decision as long as they could, ultimately placing her grandmother in a nursing home only after a severe fall, which occurred four years after she had initially moved in with them.  

Placing a loved one in a care facility can bring feelings of guilt and doubt, as Michelle shared, “Now that she’s in a facility, we rely on others to care for her, but it’s hard not knowing if she’s being treated as well as we would treat her. We do random pop-in visits just to check,”. This level of vigilance reflects the emotional toll caregiving takes. Families grapple with letting go of the person they once knew while adapting to a new reality—a painful yet necessary process. Vania observed, “Families often struggle with letting go of the version of their loved one they remember. They have to adapt and accept the new reality, which is really hard.” 

But even amidst these struggles, moments of connection remain. Michelle recounted how her grandmother’s humor shines through, offering a glimpse of the person she’s always known. “Even now, she’ll still give jokes and make us laugh. She can look at me and still switch a pen in my left hand to my right because she thinks being left-handed is wrong”, Michelle shared. 

A Holistic Approach to Caregiving 

Until science offers a cure, caregiving remains the cornerstone of Alzheimer’s management. Vania emphasized the importance of a patient-centered approach: “We’ve learned that reorienting them isn’t the way to treat them. Now, we go to where they are. If they think they need to go to work, you say, ‘Today you have the day off.’ If they ask for their car keys, you say, ‘Your car’s in the shop.’ It causes much less distress.” Such strategies require empathy and creativity, but they can significantly improve patients’ well-being. Caregivers must also learn to interpret nonverbal cues, as agitation or confusion may signal unmet needs. “When they become agitated, you have to ask yourself: Are they hungry? Are they in pain? Are they tired? Sometimes it’s as simple as giving them a snack to make them content.”  

Policy and Support 

Both Vania and Michelle highlighted systemic gaps that make Alzheimer’s care even more challenging. Vania pointed out the limitations of existing insurance structures: “Many patients don’t qualify for long-term care insurance because they can still dress or feed themselves, but they still can’t be left alone. It’s a terrible gray area where families are stuck.” She also called for more resources to support caregivers. “Families need more support. It would help if Medicare provided subsidies for care, like adult daycare programs, so caregivers could get a break”, Vania explained. These insights underscore the need for advocacy and reform to ensure that families don’t face these challenges alone.  

Michelle and her family had to rely on a loan due to the expenses required. “My mom was retired and took the days, I handled evenings, and my sister helped at night. We worked in shifts, but it was mentally, physically, and financially taxing. We converted part of our house to make accommodations so that she would have all her needs in one room”, she explained. 

A Message of Gratitude and Hope 

Despite the heartbreak, both women found meaning in their experiences. Vania expressed deep admiration for those working with Alzheimer’s patients: “Shout out to all the caregivers and those working with this population. It can be exhausting and heartbreaking, but it can also be very rewarding.” Michelle urged others to treasure the moments they still have. “Just be grateful you still have them here. Take it one day at a time and focus on the memories.” 

As we observe Alzheimer’s Awareness Month, let’s honor the caregivers, families, and patients who face this journey with courage and compassion. At Athari BioSciences, we are committed to driving innovation in Alzheimer’s research, offering hope for a future where this disease no longer defines so many lives. While the disease is influenced by lifestyle and environmental factors, genetics also plays a critical role. We are leveraging our expertise to explore how genomic insights can inform precision medicine. Our goal is to develop therapies that address the root causes of Alzheimer’s rather than just its symptoms, offering hope for earlier interventions and better outcomes. Together, through science and humanity, we can make that vision a reality.